Overview
Braeburn focuses on developing next-generation medications for opioid use disorder (OUD) and sells these therapies to healthcare providers, clinics, and patients with the aim of supporting recovery. The medicines are intended to be used together with counseling and support services as part of a comprehensive treatment plan for OUD. The company advances its goal through research, development, and commercialization of therapies, often in partnerships with other healthcare organizations, within the regulated pharmaceutical market. Unlike many generic care models, Braeburn emphasizes a mission-driven approach that combines medical treatments with patient support to help individuals reintegrate into their communities. The overall aim is to reduce the opioid crisis by providing effective, accessible treatments that help patients overcome addiction and rebuild their lives.
Work here?Claim your company
Simplify's Take
What believers are saying
- Braeburn published 2026 CPDD and ASCP data showing withdrawal suppression and retention benefits.
- Camurus said Brixadi captured roughly 32% of U.S. long-acting buprenorphine units in Q1 2026.
- September 2026 JSAT safety analysis strengthens Braeburn's postmarketing evidence for prescribers and payers.
What critics are saying
- Brixadi's intravenous misuse risk triggers REMS restrictions and serious-harm warnings across 2026 labeling.
- Indivior's Sublocade remains the category leader, limiting Braeburn's pricing power through 2026.
- Reported Camurus acquisition talks in September 2026 signal Braeburn's standalone future is uncertain.
What makes Braeburn unique
- Brixadi offers weekly and monthly buprenorphine injections with room-temperature storage, unlike many rivals.
- Braeburn expanded its U.S. commercial and medical affairs teams during 2026 for Brixadi adoption.
- Camurus reported Braeburn drove 42% royalty growth in 2026 from U.S. Brixadi uptake.
Help us improve and share your feedback! Did you find this helpful?